Terms: = Thyroid cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL
44 results:
1. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast cancer and Beyond.
Wu J; Subbiah V
Cancer Res; 2023 Oct; 83(19):3159-3161. PubMed ID: 37779428
[TBL] [Abstract] [Full Text] [Related]
2. Hashimoto's thyroiditis is negatively associated with lymph node metastasis in PTMC.
Huang H; Xu S; Ni S; Liu W; Liu S
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15525-15533. PubMed ID: 37646829
[TBL] [Abstract] [Full Text] [Related]
3. Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study.
Kim M; Kang YE; Park YJ; Koo BS; Ku EJ; Choi JY; Lee EK; Kim BH
Endocrine; 2023 Oct; 82(1):134-142. PubMed ID: 37516686
[TBL] [Abstract] [Full Text] [Related]
4. Body Mass Index and thyroid cancer Risk: A Pooled Analysis of Half a Million Men and Women in the Asia Cohort Consortium.
Shin A; Cho S; Jang D; Abe SK; Saito E; Rahman MS; Islam MR; Sawada N; Shu XO; Koh WP; Sadakane A; Tsuji I; Sugawara Y; Ito H; Nagata C; Park SK; Yuan JM; Kim J; Tsugane S; Cai H; Wen W; Ozasa K; Matsuyama S; Kanemura S; Oze I; Wada K; Wang R; Yoo KY; Potter JD; Ahsan H; Boffetta P; Chia KS; Matsuo K; Qiao YL; Rothman N; Zheng W; Inoue M; Kang D
Thyroid; 2022 Mar; 32(3):306-314. PubMed ID: 34915752
[No Abstract] [Full Text] [Related]
5. Association among Body Mass Index, Genetic Variants of FTO, and thyroid cancer Risk: A Hospital-Based Case-Control Study of the cancer Screenee Cohort in Korea.
Hoang T; Song D; Lee J; Lee EK; Hwangbo Y; Kim J
Cancer Res Treat; 2021 Jul; 53(3):857-873. PubMed ID: 33285050
[TBL] [Abstract] [Full Text] [Related]
6. [Expression of NR4A3/NOR-1 in acinic cell carcinoma of the salivary gland].
Cheng K; Wang X; Wei X; Ma J; Xia QY; Shi QL; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1142-1146. PubMed ID: 33152819
[No Abstract] [Full Text] [Related]
7. Nine Genes Mediate the Therapeutic Effects of Iodine-131 Radiotherapy in thyroid Carcinoma Patients.
Shuwen H; Xi Y; Miao D; Jiamin X; Jing Z; Weili G
Dis Markers; 2020; 2020():9369341. PubMed ID: 32626543
[TBL] [Abstract] [Full Text] [Related]
8. Metabolic syndrome risk in relation to posttraumatic stress disorder among trauma-exposed civilians in Gansu Province, China.
LIhua M; Tao Z; Hongbin M; Hui W; Caihong J; Xiaolian J
Medicine (Baltimore); 2020 Jan; 99(1):e18614. PubMed ID: 31895815
[TBL] [Abstract] [Full Text] [Related]
9. Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway.
Wu D; Tian W; Li J; Zhang Q; Wang H; Zhang L; Xie Z; Ji A; Li Y
Mol Biol Rep; 2019 Jun; 46(3):2665-2678. PubMed ID: 31028568
[TBL] [Abstract] [Full Text] [Related]
10. CPT1A regulates breast cancer-associated lymphangiogenesis via VEGF signaling.
Xiong Y; Liu Z; Zhao X; Ruan S; Zhang X; Wang S; Huang T
Biomed Pharmacother; 2018 Oct; 106():1-7. PubMed ID: 29940537
[TBL] [Abstract] [Full Text] [Related]
11. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract] [Full Text] [Related]
12. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract] [Full Text] [Related]
13. Lenvatinib in the Therapy of Aggressive thyroid cancer: State of the Art and New Perspectives with Patents Recently Applied.
Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
[TBL] [Abstract] [Full Text] [Related]
14. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
15. Next generation sequencing of extraskeletal myxoid chondrosarcoma.
Davis EJ; Wu YM; Robinson D; Schuetze SM; Baker LH; Athanikar J; Cao X; Kunju LP; Chinnaiyan AM; Chugh R
Oncotarget; 2017 Mar; 8(13):21770-21777. PubMed ID: 28423517
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy of lenvatinib in treating thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D
Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290
[TBL] [Abstract] [Full Text] [Related]
18. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary thyroid cancer.
Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
[TBL] [Abstract] [Full Text] [Related]
19. Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
[TBL] [Abstract] [Full Text] [Related]
20. Aggressive thyroid cancer: targeted therapy with sorafenib.
Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
[TBL] [Abstract] [Full Text] [Related]
[Next]
